Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting
Stoke Therapeutics Announces Plans To Present New Data That Support Zorevunersen As Potentially The First Disease-Modifying Medicine For Dravet Syndrome At The American Epilepsy Society 2024 Annual Meeting
– Company to host a virtual educational event for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific) –
公司將於美國東部時間12月9日上午8:30（太平洋時間凌晨5:30）舉辦一場虛擬的教育活動，面向投資者和研究分析師。
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific). The Company is advancing zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc.（納斯達克股票代碼：STOK）是一家專注於利用RNA藥物挖掘人體潛力恢復蛋白質表達的生物技術公司。該公司今天宣佈將在加利福尼亞洛杉磯舉行的2024年美國癲癇學會（AES）年會上進行多個演示。此外，公司還將於12月6日至10日舉辦一場虛擬活動，旨在討論受領先臨床醫生和患者倡導者引領的議題，以供投資者和研究分析師參與。該公司正在推進zorevunersen作爲治療Dravet綜合徵的潛在首個疾病修飾藥物。
